Literature DB >> 8454331

Immunochemistry of capsular type polysaccharide and virulence properties of type VI Streptococcus agalactiae (group B streptococci).

C von Hunolstein1, S D'Ascenzi, B Wagner, J Jelínková, G Alfarone, S Recchia, M Wagner, G Orefici.   

Abstract

The immunochemistry of capsular type polysaccharide and virulence characteristics of group B streptococci (GBS), type VI, were studied. By high-pressure anion-exchange chromatography and pulsed amperometric detection, as well as by 13C nuclear magnetic resonance analysis, both extracellular and cell-bound polysaccharides were found to contain glucose, galactose, and N-acetylneuraminic acid in the molar ratio of 2:2:1, respectively. At variance with all other GBS serotypes described to date (Ia, Ib, II, III, IV, and V), no N-acetylglucosamine was present, whatever the source of the material (secreted or cell bound; reference or clinical isolate). Sialic acid was probably involved in the immunodeterminant structure of this new serotype since cleavage of this sugar from the polysaccharide gave rise to an antigen which reacted very weakly with type VI antiserum and to a precipitation line in immunodiffusion with no identity with the native type VI polysaccharide. By using type VI antiserum and the protein A-gold technique, a large capsule was observed in the type VI GBS reference strain by electron microscopy. All type VI strains examined were lethal for CD-1 mice, the 50% lethal dose after intraperitoneal challenge ranging from 1.0 (+/- 0.9, standard deviation) x 10(5) to 2.5 (+/- 1.5, standard deviation) x 10(5) CFU per mouse. A rabbit antiserum against capsular type polysaccharide exhibited both protective activity for mice injected intraperitoneally with type VI reference strain or with clinical isolates and opsonic activity in a phagocytosis assay.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8454331      PMCID: PMC281358          DOI: 10.1128/iai.61.4.1272-1280.1993

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  38 in total

1.  Structural determination of the sialic acid polysaccharide antigens of Neisseria meningitidis serogroups B and C with carbon 13 nuclear magnetic resonance.

Authors:  A K Bhattacharjee; H J Jennings; C P Kenny; A Martin; I C Smith
Journal:  J Biol Chem       Date:  1975-03-10       Impact factor: 5.157

2.  Group B streptococcal infections. Perinatal impact and prevention methods.

Authors:  C J Baker; M S Edwards
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

3.  Structural determination of the capsular polysaccharide antigen of type II group B Streptococcus.

Authors:  H J Jennings; K G Rosell; E Katzenellenbogen; D L Kasper
Journal:  J Biol Chem       Date:  1983-02-10       Impact factor: 5.157

4.  Structure of native polysaccharide antigens of type Ia and type Ib group B Streptococcus.

Authors:  H J Jennings; E Katzenellenbogen; C Lugowski; D L Kasper
Journal:  Biochemistry       Date:  1983-03-01       Impact factor: 3.162

5.  Experimental model of type IV Streptococcus agalactiae (group B streptococcus) infection in mice with early development of septic arthritis.

Authors:  L Tissi; P Marconi; P Mosci; L Merletti; P Cornacchione; E Rosati; S Recchia; C von Hunolstein; G Orefici
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

6.  Antibody-independent and -dependent opsonization of group B Streptococcus requires the first component of complement C1.

Authors:  N J Levy; D L Kasper
Journal:  Infect Immun       Date:  1985-07       Impact factor: 3.441

7.  A sialic-acid-specific lectin from Cepaea hortensis that promotes phagocytosis of a group-B, type-Ia, streptococcal strain.

Authors:  S E Holm; A M Bergholm; B Wagner; M Wagner
Journal:  J Med Microbiol       Date:  1985-06       Impact factor: 2.472

8.  Detection of group B streptococcal antibodies in human sera by radioimmunoassay: concentrations of type-specific antibodies in sera of adults and infants infected with group B streptococci.

Authors:  H W Wilkinson
Journal:  J Clin Microbiol       Date:  1978-02       Impact factor: 5.948

9.  Isolation and characterization of type IV group B Streptococcus capsular polysaccharide.

Authors:  M R Wessels; W J Benedí; H J Jennings; F Michon; J L DiFabio; D L Kasper
Journal:  Infect Immun       Date:  1989-04       Impact factor: 3.441

10.  Structural and conformational analysis of sialyloligosaccharides using carbon-13 nuclear magnetic resonance spectroscopy.

Authors:  E Berman
Journal:  Biochemistry       Date:  1984-07-31       Impact factor: 3.162

View more
  11 in total

1.  Soluble antigens from group B streptococci induce cytokine production in human blood cultures.

Authors:  C von Hunolstein; A Totolian; G Alfarone; G Mancuso; V Cusumano; G Teti; G Orefici
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

2.  Structure of the type IX group B Streptococcus capsular polysaccharide and its evolutionary relationship with types V and VII.

Authors:  Francesco Berti; Edmondo Campisi; Chiara Toniolo; Laura Morelli; Stefano Crotti; Roberto Rosini; Maria Rosaria Romano; Vittoria Pinto; Barbara Brogioni; Giulia Torricelli; Robert Janulczyk; Guido Grandi; Immaculada Margarit
Journal:  J Biol Chem       Date:  2014-07-02       Impact factor: 5.157

3.  Group B streptococcal capsular sialic acids interact with siglecs (immunoglobulin-like lectins) on human leukocytes.

Authors:  Aaron F Carlin; Amanda L Lewis; Ajit Varki; Victor Nizet
Journal:  J Bacteriol       Date:  2006-09-22       Impact factor: 3.490

4.  Structural and genetic diversity of group B streptococcus capsular polysaccharides.

Authors:  Michael J Cieslewicz; Donald Chaffin; Gustavo Glusman; Dennis Kasper; Anup Madan; Stephani Rodrigues; Jessica Fahey; Michael R Wessels; Craig E Rubens
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

5.  Genotyping of the capsule gene cluster (cps) in nontypeable group B streptococci reveals two major cps allelic variants of serotypes III and VII.

Authors:  M Sellin; C Olofsson; S Håkansson; M Norgren
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

6.  Immunization with C5a peptidase or peptidase-type III polysaccharide conjugate vaccines enhances clearance of group B Streptococci from lungs of infected mice.

Authors:  Qi Cheng; Steven Debol; Hong Lam; Ron Eby; Lorri Edwards; Yury Matsuka; Stephen B Olmsted; P Patrick Cleary
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

7.  The serotype of type Ia and III group B streptococci is determined by the polymerase gene within the polycistronic capsule operon.

Authors:  D O Chaffin; S B Beres; H H Yim; C E Rubens
Journal:  J Bacteriol       Date:  2000-08       Impact factor: 3.490

8.  Molecular characterization of type-specific capsular polysaccharide biosynthesis genes of Streptococcus agalactiae type Ia.

Authors:  S Yamamoto; K Miyake; Y Koike; M Watanabe; Y Machida; M Ohta; S Iijima
Journal:  J Bacteriol       Date:  1999-09       Impact factor: 3.490

9.  Characterization of CMP-N-acetylneuraminic acid synthetase of group B streptococci.

Authors:  R F Haft; M R Wessels
Journal:  J Bacteriol       Date:  1994-12       Impact factor: 3.490

10.  L-Ficolin/mannose-binding lectin-associated serine protease complexes bind to group B streptococci primarily through N-acetylneuraminic acid of capsular polysaccharide and activate the complement pathway.

Authors:  Youko Aoyagi; Elisabeth E Adderson; Craig E Rubens; John F Bohnsack; Jin G Min; Misao Matsushita; Teizo Fujita; Yoshiyuki Okuwaki; Shinji Takahashi
Journal:  Infect Immun       Date:  2007-10-15       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.